Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 6/20 | 0.46 |
| ▸ | GSK3B | P49841 | 7/20 | 0.42 |
| ▸ | STS | P08842 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | THRA | P10827 | 1/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL32665602 | 0.88 | GSK3B (0.46) | PTPN1GSK3BMEN1KMT2A | |
| SCHEMBL32665353 | 0.81 | RAB9A (0.62) | STSHTTLMNAMAPK1RAB9A | |
| SCHEMBL32665224 | 0.80 | LMNA (0.47) | STSHTTLMNAMAPK1RAB9A | |
| SCHEMBL29620834 | 0.80 | HTT (0.65) | PTPN1GSK3BHTTLMNAMAPK1 | |
| SCHEMBL773681 | 0.80 | HTT (0.65) | PTPN1GSK3BHTTLMNAMAPK1 | |
| SCHEMBL6813745 | 0.78 | PTPN1 (0.49) | PTPN1GSK3BHTTLMNAMAPK1 | |
| SCHEMBL16210170 | 0.77 | EPHX2 (0.51) | PTPN1GSK3BHTTLMNAMAPK1 | |
| SCHEMBL32665625 | 0.76 | GSK3B (0.58) | PTPN1GSK3BSTS | |
| SCHEMBL32665621 | 0.75 | EPHX2 (0.43) | STSLMNAMEN1KMT2AALDH1A1 | |
| SCHEMBL3368165 | 0.75 | PTPN1 (0.57) | PTPN1GSK3BHTTLMNAMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260021192-A1 | PROTEINS HAVING A COVALENT WARHEAD | TOPAZ THERAPEUTICS INC (US) | 2026-01-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260021192-A1 | PROTEINS HAVING A COVALENT WARHEAD | RIOX2, ORC3, DCLRE1A | PTPN1 4150/4885GSK3B 3967/4885STS 3493/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.